메뉴 건너뛰기




Volumn 8, Issue 1, 2015, Pages 25-32

Von willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction

Author keywords

Diastolic heart failure; Prognosis; Von Willebrand factor

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; VON WILLEBRAND FACTOR; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

EID: 84925022502     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001478     Document Type: Article
Times cited : (25)

References (29)
  • 2
    • 79952829685 scopus 로고    scopus 로고
    • Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment
    • Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-679.
    • (2011) Eur Heart J. , vol.32 , pp. 670-679
    • Borlaug, B.A.1    Paulus, W.J.2
  • 4
    • 76849111852 scopus 로고    scopus 로고
    • Natriuretic peptides in heart failure: Should therapy be guided by BNP levels?
    • O'Donoghue M, Braunwald E. Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol. 2010;7:13-20.
    • (2010) Nat Rev Cardiol , vol.7 , pp. 13-20
    • O'donoghue, M.1    Braunwald, E.2
  • 6
    • 84879748718 scopus 로고    scopus 로고
    • A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
    • Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271.
    • (2013) J Am Coll Cardiol. , vol.62 , pp. 263-271
    • Paulus, W.J.1    Tschöpe, C.2
  • 10
    • 84857766493 scopus 로고    scopus 로고
    • Endothelium-role in regulation of coagulation and inflammation
    • van Hinsbergh VW. Endothelium-role in regulation of coagulation and inflammation. Semin Immunopathol. 2012;34:93-106.
    • (2012) Semin Immunopathol. , vol.34 , pp. 93-106
    • Van Hinsbergh, V.W.1
  • 11
    • 0028909230 scopus 로고
    • Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
    • European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
    • Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635-641.
    • (1995) N Engl J Med. , vol.332 , pp. 635-641
    • Thompson, S.G.1    Kienast, J.2    Pyke, S.D.3    Haverkate, F.4    Van De Loo, J.C.5
  • 13
    • 0034937299 scopus 로고    scopus 로고
    • Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease
    • LURIC Study Group (LUdwigshafen RIsk and Cardiovascular Health)
    • Winkelmann BR, März W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J; LURIC Study Group (LUdwigshafen RIsk and Cardiovascular Health). Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics. 2001;2(1 suppl 1):S1-73.
    • (2001) Pharmacogenomics. , vol.2 , Issue.1 , pp. S1-73
    • Winkelmann, B.R.1    März, W.2    Boehm, B.O.3    Zotz, R.4    Hager, J.5    Hellstern, P.6    Senges, J.7
  • 14
    • 78649477601 scopus 로고    scopus 로고
    • Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
    • Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
    • (2011) Stat Med. , vol.30 , pp. 11-21
    • Pencina, M.J.1    Steyerberg, E.W.2
  • 15
    • 33646771330 scopus 로고    scopus 로고
    • Von Willebrand factor, endothelial dysfunction, and cardiovascular disease
    • Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4:1186-1193.
    • (2006) J Thromb Haemost. , vol.4 , pp. 1186-1193
    • Vischer, U.M.1
  • 16
    • 12844253061 scopus 로고    scopus 로고
    • Endothelial function: Cardiac events
    • Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111:363-368.
    • (2005) Circulation. , vol.111 , pp. 363-368
    • Lerman, A.1    Zeiher, A.M.2
  • 17
    • 3042839778 scopus 로고    scopus 로고
    • Effects of inflammatory cytokines on the release and cleavage of the endothelial cellderived ultralarge von Willebrand factor multimers under flow
    • Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cellderived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104:100-106.
    • (2004) Blood. , vol.104 , pp. 100-106
    • Bernardo, A.1    Ball, C.2    Nolasco, L.3    Moake, J.F.4    Dong, J.F.5
  • 18
    • 0035957410 scopus 로고    scopus 로고
    • Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factordeficient mice
    • Denis CV, André P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factordeficient mice. Proc Natl Acad Sci U S A. 2001;98:4072-4077.
    • (2001) Proc Natl Acad Sci U S A. , vol.98 , pp. 4072-4077
    • Denis, C.V.1    André, P.2    Saffaripour, S.3    Wagner, D.D.4
  • 23
    • 32844474144 scopus 로고    scopus 로고
    • Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes
    • Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, Lip GY. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol. 2006;97:671-675.
    • (2006) Am J Cardiol. , vol.97 , pp. 671-675
    • Chong, A.Y.1    Freestone, B.2    Patel, J.3    Lim, H.S.4    Hughes, E.5    Blann, A.D.6    Lip, G.Y.7
  • 24
    • 33847780361 scopus 로고    scopus 로고
    • Viewpoint: The prothrombotic state in heart failure: A maladaptive inflammatory response?
    • Chong AY, Lip GY. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response? Eur J Heart Fail. 2007;9:124-128.
    • (2007) Eur J Heart Fail , vol.9 , pp. 124-128
    • Chong, A.Y.1    Lip, G.Y.2
  • 26
    • 84878339678 scopus 로고    scopus 로고
    • How do patients with heart failure with preserved ejection fraction die?
    • Chan MM, Lam CS. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail. 2013;15:604-613.
    • (2013) Eur J Heart Fail , vol.15 , pp. 604-613
    • Chan, M.M.1    Lam, C.S.2
  • 27
    • 0027236046 scopus 로고
    • Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. the Atherosclerosis Risk in Communities (ARIC) Study
    • Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70:380-385.
    • (1993) Thromb Haemost. , vol.70 , pp. 380-385
    • Conlan, M.G.1    Folsom, A.R.2    Finch, A.3    Davis, C.E.4    Sorlie, P.5    Marcucci, G.6    Wu, K.K.7
  • 29
    • 79958796133 scopus 로고    scopus 로고
    • Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients
    • Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011;57:2496-2504.
    • (2011) J Am Coll Cardiol. , vol.57 , pp. 2496-2504
    • Roldán, V.1    Marín, F.2    Muiña, B.3    Torregrosa, J.M.4    Hernández-Romero, D.5    Valdés, M.6    Vicente, V.7    Lip, G.Y.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.